Company Encyclopedia
View More
name
Regeneron Pharma
REGN.US
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company’s products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia (HoFH) or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults.
1.945 T
REGN.USMarket value -Rank by Market Cap -/-

Financial Score

26/12/2025 Update
B
BiotechnologyIndustry
Industry Ranking7/400
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreA
    • ROE15.19%A
    • Profit Margin32.13%A
    • Gross Margin46.82%B
  • Growth ScoreC
    • Revenue YoY2.89%C
    • Net Profit YoY-1.64%C
    • Total Assets YoY7.28%B
    • Net Assets YoY5.56%B
  • Cash ScoreC
    • Cash Flow Margin311.22%C
    • OCF YoY2.89%C
  • Operating ScoreC
    • Turnover0.37C
  • Debt ScoreA
    • Gearing Ratio22.93%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    10 Health Care Stocks Whale Activity In Today's Session

    Today's session highlights significant whale activity in healthcare stocks, with options trading showing varied sentiments. Notable trades include bearish calls for MRK and PFE, bullish calls for LLY and REGN, and bullish puts for MRUS and ZTS. Neutral trades were observed for MDGL and NTLA. These activities indicate potential trading opportunities as option prices diverge from their normal values.

    benzinga_article·
    US
    LLY
    +0.50%
    US
    MRUS
    +0.01%
    US
    REGN
    -0.19%
    benzinga_article·
    US
    LLY
    +0.50%
    US
    MRUS
    +0.01%
    US
    REGN
    -0.19%

    Regeneron Pharmaceuticals's Options Frenzy: What You Need to Know

    Investors are showing interest in Regeneron Pharmaceuticals with significant options activity detected. The sentiment is mixed, with 38% bullish and 30% bearish. Major market movers focus on a price band between $400 and $1000. Analysts have varied ratings, with price targets ranging from $745 to $850. The stock is currently trading at $778, down 0.17%. Options trading presents higher risks and rewards, requiring careful monitoring and strategy adaptation.

    benzinga_article·
    US
    REGN
    -0.19%
    benzinga_article·
    US
    REGN
    -0.19%

    Dupixent® (dupilumab) Approved in Japan for Children Aged 6 to 11 Years with Bronchial Asthma | REGN Stock News

    Regeneron Pharmaceuticals and Sanofi announced that Japan's Ministry of Health, Labour and Welfare approved Dupixent® (dupilumab) for children aged 6 to 11 with severe asthma. This approval is based on a Phase 3 trial showing significant reduction in exacerbations and improved lung function. Dupixent is the first biologic to show such benefits in this age group. It is already approved for various conditions in over 60 countries.

    StockTitan·
    US
    SNYNF
    -1.23%
    US
    REGN
    -0.19%
    StockTitan·
    US
    SNYNF
    -1.23%
    US
    REGN
    -0.19%

    Regeneron to Present at J.P. Morgan Healthcare Conference

    Regeneron Pharmaceuticals Inc. will webcast its presentation at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026. The presentation will be accessible via the "Investors & Media" page on Regeneron's website, with a replay and transcript available for 30 days. This announcement was originally published by Regeneron via GlobeNewswire on December 22, 2025.

    Reuters·
    US
    REGN
    -0.19%
    Reuters·
    US
    REGN
    -0.19%

    Regeneron Pharmaceuticals (NASDAQ:REGN) Downgraded to Hold Rating by Wall Street Zen

    Wall Street Zen downgraded Regeneron Pharmaceuticals from a "buy" to a "hold" rating. Other analysts have varied opinions, with some upgrading to "strong-buy" and others adjusting price targets. The stock has a consensus "Moderate Buy" rating with a target price of $779.45. Recent insider trading and institutional investments are also noted.

    Market Beat·
    US
    REGN
    -0.19%
    Market Beat·
    US
    REGN
    -0.19%
    Posts
    View More

    $Regeneron Pharma(REGN.US) plunged in pre-market trading. The core trigger was the simultaneous announcement of two Phase III trial results (one success, one failure) for Itepekimab, a COPD biologic d...

    • 0

    $Regeneron Pharma(REGN.US) This pre-market plunge is not a fake drop.

    $Taiwan Semiconductor(TSM.US)$Regeneron Pharma(REGN.US)$PDD(PDD.US) This year's US stock portfolio performance curve. Pharmaceuticals and Chinese concept stocks have protected a large portion.

    • 0
    © 2025 Longbridge｜Disclaimer